Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX07 + serplulimab + chemotherapy versus placebo + serplulimab + chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma
CTR20222662Phase 2Completed
- Sponsor
- HyBioPharma
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of pimurutamab, serplulimab in nasopharyngeal carcinoma (NPC), sponsored by HyBioPharma. Started Jan 2023; status: completed.
02
Drugs
pimurutamabserplulimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on CTR20222662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222662.